 Paclitaxel
"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 3 | 7 | | 1997 | 5 | 0 | 5 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 2 | 1 | 3 | | 2001 | 1 | 8 | 9 | | 2002 | 2 | 4 | 6 | | 2003 | 2 | 4 | 6 | | 2004 | 2 | 4 | 6 | | 2005 | 2 | 4 | 6 | | 2006 | 4 | 3 | 7 | | 2007 | 2 | 3 | 5 | | 2008 | 2 | 3 | 5 | | 2009 | 2 | 5 | 7 | | 2010 | 0 | 4 | 4 | | 2011 | 3 | 4 | 7 | | 2012 | 2 | 7 | 9 | | 2013 | 3 | 5 | 8 | | 2014 | 5 | 2 | 7 | | 2015 | 3 | 4 | 7 | | 2016 | 3 | 5 | 8 | | 2017 | 5 | 5 | 10 | | 2018 | 2 | 2 | 4 | | 2019 | 6 | 7 | 13 | | 2020 | 3 | 9 | 12 | | 2021 | 2 | 7 | 9 | | 2022 | 1 | 8 | 9 | | 2023 | 0 | 2 | 2 | | 2024 | 2 | 4 | 6 | | 2025 | 2 | 9 | 11 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Narayan A, Leibrandt RC, Lee JS, Dall'Era MA, Whitson JM, Chandrasekar T, Braun A, Mossanen M, Li H, Lara PN, Lam KS, Pan CX, Parikh M. A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer. Nanomedicine (Lond). 2026 06; 21(12):1707-1712.
-
Epeldegui M, Moser C, Choi Y, Borok M, Campbell TB, MacPhail P, Hosseinipour MC, Samaneka W, Nyirenda M, Kosgei J, Busakhala N, Martinez-Maza O, Krown SE. Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings. J Acquir Immune Defic Syndr. 2026 Apr 01; 101(4):416-423.
-
Lu T, Hamidi H, Socinski MA, Reck M, Cappuzzo F, Barlesi F, Jotte RM, Müller S, Qamra A, Amitai A, Guan X, Fuentes E, Koeppen H, Giltnane JM, Shames DS, Ballinger M, He MX, Wang Y, Srivastava MK, Nabet BY. Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. Nat Commun. 2025 Dec 03; 17(1):122.
-
Bakhtiar M, Razi S, Ahmed R, Mahnoor M, Ismail A, AlMasri S, Nunns G, Paniccia A, Ongchin MC, Zureikat A, Pingpank J, Choudry H, Saeed A. Efficacy and safety of intraperitoneal paclitaxel-based regimens in patients with gastric cancer and peritoneal metastasis: A systematic review and meta-analysis. Eur J Surg Oncol. 2026 01; 52(1):111299.
-
Cohen DJ, Goldberg JD, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott AJ, Bekaii-Saab T, Messersmith WA, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Oncologist. 2025 Oct 01; 30(10).
-
Groisser A, Frantz A, Geller JI, Ortiz MV, Walterhouse D, Ranalli M, Woods-Swafford W, Schoettler P, Garrington T, Mullen EA, Ash S, Bardhan P, Balis F, Dome JS. Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatr Blood Cancer. 2025 Oct; 72(10):e31915.
-
Omiya K, Oba A, Sugiura K, Maekawa A, Mie T, Kobayashi K, Ono Y, Sasaki T, Ozaka M, Sasahira N, Ito H, Inoue Y, Takahashi Y. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Aug; 32(8):5411-5420.
-
Stoop TF, Wu YHA, Oba A, Ali M, Feld IM, Al-Musawi MH, Jain A, Saiura A, Sauvanet A, Coppola A, Javed AA, Groot Koerkamp B, Miller BN, Hashimoto D, Caputo D, Kleive D, Sereni E, Kazemier G, Belfiori G, Ishida H, van Dam JL, Dembinski J, Akahoshi K, Roberts KJ, Tanaka K, Labori KJ, Falconi M, House MG, Sugimoto M, Tanabe M, Gotohda N, Chatzizacharias N, Krohn PS, Dokmak S, Rodriguez Franco S, Hirano S, Burgdorf SK, Crippa S, Satoi S, Nguyen TK, Yamamoto T, Nakamura T, Ushida Y, Bachu V, Burns WR, Inoue Y, Takahashi Y, Aslami Z, Schulick RD, He J, Messersmith W, Besselink MG, Burkhart RA, Wilmink JW, Del Chiaro M. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study. Br J Cancer. 2025 Jul; 133(1):76-84.
-
Ono Y, Ito R, Kobayashi K, Oba A, Sato T, Ito H, Inoue Y, Takahashi Y. Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2025 Jun; 32(6):4417-4418.
-
Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|